Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-21
    E.g., 2018-09-21

Archive Search

7 results
12:00 AM, Feb 10, 2014  |  BC Week In Review | Clinical News  |  Clinical Results

ADX71149: Phase IIa data

to treat schizophrenia. In 2005, Addex and Janssen partnered to discover, develop and commercialize worldwide mGluR2
Product: ADX71149 , JNJ-40411813   Business: Neurology   Molecular target: Metabotropic glutamate receptor subtype 2 (mGluR2
GRM2)   Description: Positive allosteric modulator (PAM) of metabotropic glutamate receptor subtype 2 (mGluR2)   Indication: Treat major depressive disorder …
12:00 AM, Dec 17, 2012  |  BC Week In Review | Clinical News  |  Clinical Results

BCI-838: Phase I data

Japan   Product: BCI-838   Business: Neurology   Molecular target: Metabotropic glutamate receptor subtype 2 (mGluR2
Metabotropic glutamate receptor subtype 3 (mGluR3) (GRM3)   Description: Oral prodrug of BCI-632, a metabotropic glutamate receptor subtype 2
mGluR2; GRM2) and mGluR3 antagonist   Indication: Treat major depressive disorder (MDD) and treatment-resistant depression (TRD …
12:00 AM, Nov 19, 2012  |  BC Week In Review | Clinical News  |  Clinical Results

ADX71149: Phase IIa data

major depressive disorder (MDD). In 2004, Addex and J&J partnered to discover, develop and commercialize mGluR2
Product: ADX71149 , JNJ-40411813   Business: Neurology   Molecular target: Metabotropic glutamate receptor subtype 2 (mGluR2
GRM2)   Description: Positive allosteric modulator (PAM) of metabotropic glutamate receptor subtype 2 (mGluR2)   Indication: Treat schizophrenia   Endpoint …
12:00 AM, Sep 03, 2012  |  BC Week In Review | Clinical News  |  Clinical Results

Pomaglumetad methionil: Development discontinued

Pomaglumetad methionil (mGlu2/3) (LY2140023)   Business: Neurology   Molecular target: Metabotropic glutamate receptor subtype 2 (mGluR2
Metabotropic glutamate receptor subtype 3 (mGluR3) (GRM3)   Description: Oral prodrug of LY404039, a metabotropic glutamate receptor subtype 2/3 …
mGluR2/3) agonist   Indication: Treat acute schizophrenia   Endpoint: Change from baseline in Positive and Negative …
12:00 AM, Jul 16, 2012  |  BC Week In Review | Clinical News  |  Clinical Results

Pomaglumetad methionil: Phase IIb data

LY2140023 )   Business: Neurology   Molecular target: Metabotropic glutamate receptor subtype 2 (mGluR2
Metabotropic glutamate receptor subtype 3 (mGluR3) (GRM3)   Description: Oral prodrug of LY404039, a metabotropic glutamate receptor subtype 2/3 …
mGluR2/3) agonist   Indication: Treat acute schizophrenia   Endpoint: Change from baseline in Positive and Negative …
12:00 AM, Mar 12, 2012  |  BC Week In Review | Clinical News  |  Clinical Results

BCI-838: Phase I data

Japan   Product: BCI-838   Business: Neurology   Molecular target: Metabotropic glutamate receptor subtype 2 (mGluR2
Metabotropic glutamate receptor subtype 3 (mGluR3) (GRM3)   Description: Oral prodrug of BCI-632, a metabotropic glutamate receptor subtype 2
mGluR2; GRM2) and mGluR3 antagonist   Indication: Treat major depressive disorder (MDD) and treatment-resistant depression   …
12:00 AM, Apr 06, 2009  |  BC Week In Review | Clinical News  |  Clinical Results

LY2140023: Phase II data

Lilly and Co. (NYSE:LLY), Indianapolis, Ind.   Product: LY2140023   Business: Neurology   Molecular target: Metabotropic glutamate receptor subtype 2
3 ( mGluR2 /3)   Description: Oral prodrug of LY404039, a glutamate 2/3 (mGlu2/3) receptor agonist …